Orkambi and Symkevi have been rejected by the Scotland Medicines Consortium (SMC) due to their conclusion that the costs outweigh the benefits.
smc
-
August 16, 2019
Orkambi and Symkevi have been rejected by the Scotland Medicines Consortium (SMC) due to their conclusion that the costs outweigh the benefits.